Heart Diseases Cies Search Engine [selected websites]

Thursday, December 2, 2010

Micell Technologies : First Patient in DESSOLVE I First-In-Human Study of MiStent DES

Micell TechnologiesNovember 29, 2010- MiStent DES Delivers Sirolimus via Bioabsorbable Polymer; Drug and Polymer are Designed to be Eliminated within 90 days with Optimized Dissolution Kinetics - Micell Technologies,™ Inc. announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries), a first-in-human clinical trial of the company’s investigational MiStent™ Drug Eluting Coronary Stent System (MiStent DES).

DESSOLVE I is a prospective, open-label, non-randomized, single-arm study that is expected to enroll 30 patients at five clinical sites in Belgium, Australia and New Zealand. Candidates for the trial are patients with documented stable or unstable angina pectoris or ischemia. The primary endpoint is in-stent late lumen loss, as measured with angiography in treated de novo lesions ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 23 mm long stent.

Along with secondary clinical endpoints such as major adverse cardiac events and revascularization rates, intravascular ultrasound (IVUS) and optical coherence tomography (OCT) will also be employed at multiple timepoints. The DESSOLVE I study uses multiple imaging modalities to better understand the time to complete tissue coverage of the stent struts relative to polymer absorption... [PDF] Micell Technologies' Press Release -